KIT and gastrointestinal stromal tumor: Most gastrointestinal stromal tumors (GISTs) are driven by activating oncogenic mutations of receptor tyrosine kinase (RTK) KIT/PDGFRA, which provide a compelling therapeutic target, as evidenced by the clinical successes of KIT/PDGFRA-inhibition by small molecule therapeutics.